{
  "id": 19360329,
  "title": "Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study",
  "url": "https://urgent.news/2026/11/10/beam-says-base-edited-sickle-cell-therapy-succeeds-in-phase-1-2-study",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T16:23:21.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/beam-says-base-edited-sickle-cell-therapy-succeeds-in-phase-1-2-study/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Beam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon enter the market. In Beam’s Phase 1/2 trial, known as ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Beam’s base editing therapy for sickle cell hits goal in pivotal trial",
        "url": "https://urgent.news/2026/11/10/beams-base-editing-therapy-for-sickle-cell-hits-goal-in-pivotal-trial",
        "published": "2026-11-10T17:06:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}